top of page

Wed, May 11

|

Guelph

Icosapent ethyl in cardiovascular disease

Speaker: Dr. Jacek Misterski Moderator: Dr Courtney Bell

Registration is closed
See other events
Icosapent ethyl in cardiovascular disease
Icosapent ethyl in cardiovascular disease

Time & Location

May 11, 2022, 6:00 p.m.

Guelph, 49 Clair Rd E, Guelph, ON N1L 0J7, Canada

Guests

About the Event

We are inviting you to a live presentation entitled: Icosapent ethyl (IPE) in cardiovascular disease: Knowledge Translation on the New Canadian Dyslipidemia Guideline

Speaker:  Dr Jacek Misterski

Moderator: Dr. Courtney Bell

Learning Objectives: At the end of this session, the participants will be able to: Location: In compliance with Innovative Medicines Canada Code of Ethical Practices, this invitation is extended to Health Care Professionals only. This program is made possible through financial and in-kind support from HLS Therapeutics Inc. and Pfizer Canada ULC. We are inviting you to a live presentation entitled: Icosapent ethyl (IPE) in cardiovascular disease: Knowledge Translation on the New Canadian Dyslipidemia Guideline i. Recognize that persistent cardiovascular risk (PCVR) remains in statin-treated patients ii. Identify elevated triglycerides as a marker of PCVR in statin-treated patients iii. Review the evidence for cardiovascular event reduction in statin-treated patients with elevated TGs iv. Describe a recent non-statin therapy for cardiovascular event reduction in statintreated patients with elevated TGs v. Apply novel cardiovascular risk management therapies to statin-treated patients with PCVR

Share This Event

bottom of page